靶向胆管反应细胞凋亡减少胆汁淤积小鼠肝纤维化
该研究在Mdr2-/-等小鼠模型中探讨胆管反应(DR)细胞的凋亡调控。MCL1抑制剂S63845可降低DR细胞活力,静脉给药减少DR细胞群、炎症标志物及肝纤维化,并减少肝脏B淋巴细胞。DR细胞通过招募免疫细胞营造促纤维化微环境。
要点
- MCL1抑制剂S63845可诱导DR细胞凋亡。
- S63845减少小鼠肝脏DR细胞、炎症及纤维化。
- DR细胞通过趋化因子招募B细胞等免疫细胞。
核心结论
- DR细胞在招募免疫细胞、营造炎症和促纤维化微环境中起关键作用。
- 药理学靶向MCL1可减少慢性胆汁淤积小鼠的DR细胞和B细胞群体及肝纤维化。
研究设计与样本
- 研究培养野生型、Tr-/-、Mdr2-/-和双敲除(DKO)小鼠来源的EpCAM阳性反应性胆管类器官(ERC)。
- 使用单细胞转录组学和免疫染色确认ERC的DR细胞表型。
- 在Mdr2-/-和DKO小鼠中静脉给予MCL1抑制剂S63845,评估DR细胞、炎症和纤维化。
- 采用高清晰度飞行时间质谱流式细胞术评估肝脏B淋巴细胞。
- 体外和体内(原发性硬化性胆管炎肝标本)检测DR细胞凋亡启动。
主要发现
- DKO ERC显示独特翻译簇并表达趋化因子,提示反应状态。
- S63845显著降低DKO和Mdr2-/- ERC活力,与WT相比。
- S63845静脉给药显著减少Mdr2-/-和DKO小鼠的DR细胞群体及炎症和肝纤维化标志物。
- S63845治疗的DKO小鼠肝脏B淋巴细胞显著减少,与未治疗小鼠相比。
- 骨髓来源巨噬细胞与DKO小鼠肝脏ERC共培养上调B细胞趋化因子CCL5表达。
临床怎么用
- 提示靶向MCL1诱导DR细胞凋亡可能成为胆汁淤积性肝病抗纤维化策略。
- DR细胞通过招募B细胞等免疫细胞参与纤维化,需进一步临床验证。
局限性
- 研究仅基于小鼠模型和体外细胞实验,尚未在人体中验证。
- S63845的长期疗效和安全性未报告。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: In cholestatic liver diseases, ductular reactive (DR) cells extend into the hepatic parenchyma and promote inflammation and fibrosis. We have previously observed that multidrug-resistant 2 (Mdr2-/- ) double knockout (DKO) mice lacking tumor necrosis factor-related apoptosis-inducing ligand receptor (Tr-/- ) display a more extensive ductular reaction and hepatic fibrosis compared to Mdr2-/- mice. This observation suggests that the magnitude of the DR-cell population may be regulated by apoptosis. APPROACH AND RESULTS: To examine this concept, we cultured epithelial cell adhesion molecule-positive reactive cholangioids (ERCs) obtained from wild-type (WT), Tr-/- , Mdr2-/- and DKO mice. Single-cell transcriptomics and immunostaining of both WT and DKO ERCs confirmed their DR-cell phenotype. Moreover, DKO ERCs displayed a unique translational cluster with expression of chemokines, indicating a reactive state. Incubation with the myeloid cell leukemia 1 (MCL1) inhibitor S63845, a proapoptotic BH3-mimetic therapy, significantly decreased DKO and Mdr2-/- ERC viability compared to WT. Intravenous administration of S63845 significantly reduced the DR-cell population and markers of inflammation and liver fibrosis in Mdr2-/- and DKO mice. Furthermore, DKO mice treated with S63845 displayed a significant decrease in hepatic B lymphocytes compared to untreated mice as assessed by high-definition mass cytometry by time-of-flight. Coculture of bone marrow-derived macrophages with ERCs from DKO mouse livers up-regulated expression of the B cell-directed chemokine (C-C motif) ligand 5. Finally, DR cells were noted to be primed for apoptosis with Bcl-2 homologous antagonist/killer activation in vitro and in vivo in primary sclerosing cholangitis liver specimens. CONCLUSIONS: DR cells appear to play a key role in recruiting immune cells to the liver to actively create an inflammatory and profibrogenic microenvironment. Pharmacologic targeting of MCL1 in a mouse model of chronic cholestasis reduces DR-cell and B-cell populations and hepatic fibrosis.
引用
- Azad AI, Krishnan A, Troop L, et al. Targeted Apoptosis of Ductular Reactive Cells Reduces Hepatic Fibrosis in a Mouse Model of Cholestasis. Hepatology. 2020. PMID: 32128842. doi:10.1002/hep.31211
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。